Previous work demonstrated that in vivo inhibition of Gln metabolism using DRP-104 could enhance the infiltration of CD8+ T cells and increase response to immunotherapy (anti-programmed cell death protein 1) in multiple other non-PDAC tumor models, probably through impairing the function of suppressive subsets of immune cells17,26. The gene discussed is CD8A; the disease is neoplasm.